Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

被引：0
作者：
Cull, Gavin
Opat, Stephen
Trotman, Judith
Hilger, James
Zhang, Xiaoping
Feng, Shibao
Ro, Sunhee
Huang, Jane
Tam, Constantine S.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4057
引用
收藏
页数：4
相关论文
共 50 条
[31]   A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data [J].
Cheah, Chan Y. ;
Tam, Constantine S. ;
Lasica, Masa ;
Verner, Emma ;
Browett, Peter J. ;
Anderson, Mary Ann ;
Hilger, James ;
Fang, Yiqian ;
Simpson, David ;
Opat, Stephen .
BLOOD, 2022, 140 :2321-2323
[32]   The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies [J].
Cheah, Chan Yoon ;
Jurczak, Wojciech ;
Lasica, Masa ;
Wrobel, Tomasz ;
Cheung, Stanley ;
Walewski, Jan ;
Giannopoulos, Krzysztof ;
Yannakou, Costas K. ;
Lewis, Katharine L. ;
Dlugosz-Danecka, Monika ;
Miskin, Hari P. ;
Ricart, Alejandro D. ;
O'Connor, Owen A. ;
Tam, Constantine S. .
BLOOD, 2021, 138
[33]   Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study [J].
Shah, Nirav N. ;
Wang, Michael L. ;
Brown, Jennifer R. ;
Patel, Krish ;
Woyach, Jennifer A. ;
Wierda, William G. ;
Ujjani, Chaitra S. ;
Eyre, Toby A. ;
Zinzani, Pier Luigi ;
Alencar, Alvaro J. ;
Gastinne, Thomas ;
Ghia, Paolo ;
Lamanna, Nicole ;
Hoffmann, Marc ;
Patel, Manish R. ;
Flinn, Ian W. ;
Gerson, James N. ;
Ma, Shuo ;
Coombs, Catherine C. ;
Cheah, Chan Y. ;
Lech-Maranda, Ewa ;
Fakhri, Bita ;
Kim, Won-Seog ;
Barve, Minal A. ;
Cohen, Jonathon B. ;
Jurczak, Wojciech ;
Munir, Talha ;
Thompson, Meghan C. ;
Roeker, Lindsey E. ;
Bao, Katherine ;
Cangemi, Nicholas A. ;
Kherani, Jennifer F. ;
Walgren, Richard A. ;
Han, Hongmei ;
Ruppert, Amy S. ;
Mato, Anthony R. .
BLOOD, 2022, 140 :4127-4132
[34]   Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies. [J].
Soumerai, Jacob Drobnyk ;
Jagadeesh, Deepa ;
Salman, Huda S. ;
Lossos, Izidore S. ;
Asch, Adam Steven ;
Reddy, Nishitha ;
Kenkre, Vaishalee Padgaonkar ;
Pagel, John M. ;
Persky, Daniel O. ;
Awan, Farrukh Tauseef ;
Diefenbach, Catherine S. Magid ;
Huang, Wenying ;
Llorin-Sangalang, Judith ;
Gorbatchevsky, Igor ;
Zelenetz, Andrew David .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35]   Phase 1 Study of TT-01488, a Novel, Non-Covalent, Reversible BTK Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies [J].
Li, Yufu ;
Xu, Wei ;
Li, Caixia ;
He, Pengcheng ;
Yang, Wei ;
Tong, Xiangmin ;
Wang, Ying ;
Zhang, Hongchan ;
Sun, Caixia ;
Sheng, Zejuan ;
Fan, Jean ;
Li, Jianyong .
BLOOD, 2024, 144 :3037-3037
[36]   Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies [J].
Cheah, Chan Y. ;
Wickham, Nicholas ;
Yannakou, Costas K. ;
Lewis, Katharine L. ;
Hui, Chi-Hung ;
Tang, Pek Sang ;
Turpuseema, Tejasvi ;
Miskin, Hari P. ;
Tang, Jian-Ping ;
Normant, Emmanuel ;
Ricart, Alejandro D. ;
Tam, Constantine S. .
BLOOD, 2019, 134
[37]   Phase 1 dose escalation study of MH048, a novel and non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies. [J].
Cao, Guoqing ;
Jin, Zhengming ;
Li, Yuhua ;
Zhang, Liling ;
Shi, Junwei ;
Jin, Jie .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[38]   Enhancing safety and therapeutic efficacy: PD-1 inhibitor and recombinant human endostatin combination in advanced non-small cell lung cancer patients [J].
Wang, Shuhong ;
Yang, Min ;
Chen, Dan ;
Liang, Meiling .
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (06) :2483-2491
[39]   Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies. [J].
Cheah, Chan ;
Jurczak, Wojciech ;
Lasica, Masa ;
Wickham, Nicholas W. ;
Wrobel, Tomasz ;
Walewski, Jan Andrzej ;
Yannakou, Costas K. ;
Cheung, Stanley ;
Lewis, Katharine L. ;
Dlugosz-Danecka, Monika ;
Giannopoulos, Krzysztof ;
Miskin, Hari P. ;
Tang, Jian-Ping ;
Normant, Emmanuel ;
O'Connor, Owen A. ;
Ricart, Alejandro Daniel ;
Tam, Constantine Si Lun .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[40]   A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies [J].
Samaniego, Felipe ;
Burke, John M. ;
Mahadevan, Daruka ;
Cherry, Mohamad ;
Sadiq, Ahad A. ;
Koontz, M. Zach ;
Villasboas, Jose C. ;
Reid, Erin ;
Cull, Elizabeth ;
Priego, Victor ;
Roeker, Lindsey E. ;
Cobb, Patrick ;
Melear, Jason ;
Conkling, Paul ;
Cosgrove, David ;
Zhang, Hongying ;
Rastgoo, Nasrin ;
Benbatoul, Khalid ;
Haney, Donna Nguyen ;
Jin, Yuying ;
Marango, Jotin ;
Howell, Stephen B. ;
Rice, William G. ;
Bejar, Rafael .
BLOOD, 2021, 138
12345